Sirtex gives investors injection of confidence

Liver cancer treatment developer’s share price surges on its latest sales update.

Sirtex Medical (SRX) is the best performer on the Uncapped 100 this afternoon after the liver cancer treatment developer’s share price recorded its best gain in nearly a decade on its latest sales update.

Management reported dose sales of its microspheres increased 18.7% in the December quarter, which stands in stark contrast to the previous dismal sales growth of just 4% for the September quarter.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles